In the month following the withdrawal of Merck's COX-2 inhibitor Vioxx from the market, the majority of Medicaid patients who had been taking the arthritis medication were switched to other COX-2 inhibitors, according to Verispan's Vector One(TM): State Medicaid Service. When viewed at the state level, some divergent patterns emerge among individual Medicaid plans.
